BAMCO Inc
PTGX icon

BAMCO Inc’s Protagonist Therapeutics PTGX Stock Holding History

BAMCO Inc’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
16,000
+1,000
+7% +$104K ﹤0.01% 286
2026
Q1 		$1.58M Buy
15,000
+6,700
+81% +$593K ﹤0.01% 283
2025
Q4 		$725K Buy
+8,300
New +$679K ﹤0.01% 303
2022
Q1 		– Sell
-26,000
Closed -$889K – 415
2021
Q4 		$889K Buy
+26,000
New +$822K ﹤0.01% 374

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BAMCO Inc's PTGX Position: Q2 2026 in Review

BAMCO Inc increased its Protagonist Therapeutics (PTGX) stake by 6.7% in Q2 2026, buying an estimated $104K and bringing the position to 16,000 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #286.

BAMCO Inc first reported a position in PTGX in Q4 2021 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • BAMCO Inc held 16,000 shares of Protagonist Therapeutics worth $1.96M as of Q2 2026.
  • BAMCO Inc bought 1,000 Protagonist Therapeutics shares in Q2 2026, an estimated $104K.
  • Protagonist Therapeutics made up ﹤0.01% of BAMCO Inc's portfolio in Q2 2026, its #286 holding.
  • BAMCO Inc first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on BAMCO Inc's 13F filing for Q2 2026, filed 14 Aug 2026.